{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040151","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.901496+00:00","generated_at":"2026-06-11T22:39:34.625705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586","bullets":["Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.","Net loss for six months ended June 30, 2023 was $36.6M vs. $35.7M in same period 2022.","R&D expenses rose to $28.9M for six months, driven by headcount and clinical costs for PC14586.","FDA alignment obtained on recommended Phase 2 dose and key elements of registrational trial; Phase 1 data update expected 2H 2023.","Appointed Dr. Masha Poyurovsky as Vice President of Biology; ongoing combination arm with KEYTRUDA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040151","json":"https://secwatch.observer/filing/0000950170-23-040151.json","markdown":"https://secwatch.observer/filing/0000950170-23-040151.md","text":"https://secwatch.observer/filing/0000950170-23-040151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/0000950170-23-040151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/pmvp-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:39:34.625705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce43dd19e48810a75b979748ee5f1d49738a9f92","claim":"PMV Pharmaceuticals, Inc. reported Six months ended June 30, 2023 results: net income -$36.6 million.","evidence_excerpt":"Net loss for the six months ended June 30, 2023, was $36.6 million compared to $35.7 million for the six months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/0000950170-23-040151-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Six months ended June 30, 2023"},{"label":"Net income","value":"-$36.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}